Medis offers a wide portfolio of products and intellectual property to other pharmaceutical companies. Medis currently provides more than 170 pharmaceutical products for human use, mainly in the form of tablets and capsules.The R&D specialists we collaborate with maintain a strong development pipeline, enabling the timely availability of new products for our customers.

Medis has also established itself as a reliable source of pharmaceutical intellectual property. The robustness of our registration dossiers is reflected in the efficient procurement of regulatory approval prior to patent expiry of pharmaceuticals. Medis has obtained marketing authorisations in over 50 countries to date and export to most of the European nations as well as other regions of the world.

 Oncology products

Medis has stepped up its third-party sales activities with the addition of oncology products to its growing portfolio. The new products are sourced from Actavis Romania (fomerly Sindan) which is a leading European generic pharmaceutical company specialising in the manufacturing and distribution of oncology products.  Actavis acquired Sindan in March 2006 and has completed the integration of the business.  

The current oncology portfolio consists of over 15 available dossiers. Many more dossiers are expected to be completed over the next few years. 

In 2007, Medis is establishing a number of partnerships with pharmaceutical companies dedicated to the hospital market.  So, if your current or future business strategy includes a focus on hospital markets and oncology products, please feel free to contact us for further information and advice.

Please contact us through medis@medis.is for more detailed information on available dossiers and our development pipelines.